Company: INKT
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001193125-25-272532
Chunk: 38

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-11-07
Form: S-3
Chunk 38
---
AP-expressing stromal cells, and improved CD8+ infiltration. Preclinical data were presented at the American Society of
Gene and Cell Therapy (ASGCT) 2023 and American Association for Cancer Research (AACR) 2024 annual meetings. IND-enabling studies for MiNK-215 are underway.

To date, we have treated nearly 100 patients across cancer and immune-mediated indications. Our work has yielded insights into the mechanisms
driving iNKT cell activity, durability, and safety. With our vertically integrated platform, proprietary technologies, and experienced leadership team, we believe we are well positioned to deliver transformative cellular immunotherapies that can be
broadly deployed across high-burden diseases.

Corporate Information

We were incorporated as AgenTus Biosciences Inc. in Delaware in July 2017. We changed our name to AgenTus Therapeutics, Inc. in
October 2017 and to MiNK Therapeutics, Inc. in June 2021. Our principal executive offices are located at 149 Fifth Avenue Suite 500, New York, NY 10010, and our telephone number is 212-994-8250. Our website is minktherapeutics.com. Information contained on, or that can be accessed through, our website is not part of this prospectus supplement.

S-2

THE OFFERING The following summary contains basic information about our common stock and the offering and is not intended to be complete. It does not contain all the information that may be important to you. For a more complete understanding of our common stock, you should read the section entitled “Description of Common Stock” in the accompanying prospectus.

| Common stock offered by us                   |     | Shares of common stock having an aggregate offering price of up to $50,000,000.                                                                                                                                                       |
| Common stock outstanding after this offering |     | Up to 7,650,600 shares, assuming sales of 3,660,322 shares of common stock in this offering at an offering price of $13.66 per share, which was the last reported price of our shares of common stock on the Nasdaq Capital Market on 
 November 6, 2025. The actual number of shares issued will vary depending on how many shares we choose to sell under this offering.                                                                                                    |
| Plan of Distribution                         |     | “At the market offering” that may be made from time to time for our common stock in the United States through the Sales Agent.